Roche plans to pit next-gen hemophilia A antibody against Hemlibra in Phase 3
Roche is moving its next-generation hemophilia A treatment into Phase 3 testing next year after seeing the early-stage data.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
